Clementia Pharm (CMTA) Research Coverage Started at Leerink Swann
Leerink Swann started coverage on shares of Clementia Pharm (NASDAQ:CMTA) in a report released on Monday morning, Marketbeat reports. The brokerage issued an outperform rating on the stock. Leerink Swann also issued estimates for Clementia Pharm’s Q3 2017 earnings at ($0.32) EPS, Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($4.57) EPS, FY2018 earnings at ($1.17) EPS, FY2019 earnings at ($1.20) EPS, FY2020 earnings at ($1.47) EPS and FY2021 earnings at ($0.40) EPS.
A number of other research analysts also recently commented on CMTA. Wedbush began coverage on shares of Clementia Pharm in a research report on Monday. They set an outperform rating and a $26.00 target price on the stock. Morgan Stanley began coverage on shares of Clementia Pharm in a research report on Monday. They set an overweight rating and a $27.00 target price on the stock.
Clementia Pharm (NASDAQ:CMTA) opened at 16.01 on Monday. The stock’s 50 day moving average is $14.97 and its 200-day moving average is $14.97. The company’s market cap is $488.74 million. Clementia Pharm has a 52-week low of $15.05 and a 52-week high of $18.95.
Clementia Pharm Company Profile
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related companies with Analyst Ratings Network's FREE daily email newsletter.